Suriclone

Suriclone

SCHEMBL114688

CN1CCN(C(=O)OC2C3=C(SCCS3)C(=O)N2c2ccc3ccc(Cl)nc3n2)CC1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.45
MAPT P10636 1/20 0.45
RECQL P46063 1/20 0.45
GABRA1 P14867 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45
GABRA4 P48169 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTR3E A5X5Y0 1/20 0.32
HTR3B O95264 1/20 0.32
HTR3A P46098 1/20 0.32
HTR3D Q70Z44 1/20 0.32
HTR3C Q8WXA8 1/20 0.32
HRH3 Q9Y5N1 5/20 0.31
BRD4 O60885 1/20 0.31
BRDT Q58F21 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Suriclone SCHEMBL30658453 1.00 ADORA3 (0.45) ADORA3MAPTRECQLGABRA1GABRA3
SCHEMBL11486094 0.93 ADORA3 (0.37) ADORA3MAPTRECQLGABRA1GABRA3
SCHEMBL11489201 0.91 POLB (0.36) ADORA3MAPTRECQLGABRA1GABRA3
Suproclone SCHEMBL29419877 0.91 MAPT (0.36) ADORA3MAPTRECQLGABRA1GABRA3
Suproclone SCHEMBL113028 0.91 MAPT (0.36) ADORA3MAPTRECQLGABRA1GABRA3
SCHEMBL11842548 0.90 ADORA3 (0.43) ADORA3MAPTRECQLGABRA1GABRA3
SCHEMBL11485257 0.90 ADORA3 (0.35) ADORA3MAPTRECQLGABRA1GABRA3
SCHEMBL11485464 0.90 ADORA3 (0.35) ADORA3MAPTRECQLGABRA1GABRA3
SCHEMBL11486374 0.89 ADORA3 (0.34) ADORA3MAPTRECQLGABRA1GABRA3
SCHEMBL11263246 0.89 ADORA3 (0.44) ADORA3MAPTRECQLGABRA1GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2656 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024102699-A1 GUANYLATE CYCLASE (GC) STIMULATOR FORMULATIONS AND USES THEREOF ELANCO US, Inc. (US) 2024-05-16 WO claimed
US-20240148913-A1 LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING INNO MEDICINE CO., LTD. (CN) 2024-05-09 US claimed
WO-2022086835-A1 COMBINATION PRODUCTS TO MITIGATE THE RISK OF NON-BENZODIAZEPINE BENZODIAZEPINE AGONIST ADVERSE REACTION AND OVERDOSE PRESTI MICHAEL (US) 2022-04-28 WO claimed
US-20220117916-A1 Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose SAFERX PHARMACEUTICALS LLC (US) 2022-04-21 US claimed
US-20210145747-A1 CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF BEIJING INNO MEDICINE CO., LTD. (CN) 2021-05-20 US claimed
US-20200397926-A1 LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING INNO MEDICINE CO., LTD. (CN) 2020-12-24 US claimed
EP-3744317-A1 LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Inno Medicine Co., Ltd. (CN) 2020-12-02 EP claimed
US-10689373-B2 1,2-substituted cyclopentanes as orexin receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-06-23 US claimed
EP-2034951-B2 REHYDRATABLE PHARMACEUTICAL PRODUCT BIOCOMPATIBLES UK LTD (GB) 2020-03-25 EP claimed
EP-3610859-A1 CERASOME DELIVERY SYSTEM FOR USE IN TARGETED ACTIVATION OF CD44 MOLECULE, PREPARATION METHOD THEREFOR AND USE Beijing Inno Medicine Co., Ltd. (CN) 2020-02-19 EP claimed
US-20050186679-A1 Method for determining specific groups constituting heparins or low molecular weight heparins VISKOV CHRISTIAN (FR) 2005-08-25 US claimed
EP-1273301-A2 Pharmaceutical preparations based on active ingredients susceptible to illicit administration ALTERGON S.A. (CH) 2003-01-08 EP claimed
WO-2001008670-A2 METHODS AND COMPOSITIONS FOR ALLEVIATING STUTTERING INTERNEURON PHARMACEUTICALS, INC. (US) 2001-02-08 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0123585-B1 TRANSDERMAL DRUG FORM RHONE-POULENC SANTE (FR) 1988-08-31 EP claimed
US-4746509-A DISPERSION IN FILM-FORMING POLYMER RHONE-POULENC SANTE (FR) 1988-05-24 US claimed
EP-0123585-A2 Transdermal drug form RHONE-POULENC SANTE (FR) 1984-10-31 EP claimed
US-3966931-A TRANQUILIZERS, ANTICONVULSANTS, HYPNOSIS RHONE-POULENC S.A. (FR) 1976-06-29 US claimed
US-3948917-A TRANQUILIZERS, ANTICONVULSANTS, DECONTRACTURANTS, HYPNOSIS RHONE-POULENC S.A. (FR) 1976-04-06 US claimed